[Mono-bugs] RE: STOCK MARKET ALERT: PDPR Announces Increased Revenues
Gina Byers" <firstname.lastname@example.org
Sun, 25 Jan 2004 02:09:00 +0100
OTC FIRST ALERT - New Public Company of the Month
Sector: Infant-Pediatric Prosthetics
BREAKING NEWS: LAKE HARMONY, PA -- (MARKET WIRE) -- Dec. 01, 2003 --
IOCircuit.com Announces Increased Revenue PDPR. Pediatric Prosthetics, In=
has recently recruited one of the finest Pediatric Orthotists in the
BREAKING NEWS: LAKE HARMONY, PA -- (MARKET WIRE) -- Nov. 26, 2003 --
TheNewsWire.com Reiterates PDPR with a Buy Rating and announces that
Pediatric Prosthetics, Inc. is continuing its efforts to recruit new
Jim Furey of Lehman Brothers says, "You want to own small stocks versus
large stocks when economic growth is accelerating, which is exactly the
period we're in now. "
PDPR's a small NEW company that's developed a strong niche in the
Infant-Pediatric Prosthetics segment, estimated at over $100 million
The national prosthetics market is estimated at nearly $2 billion annually=
and is extremely fragmented. PDPR's infant segment of this market, ages =
to 14 comprise of 5% or $100 million of the total $2 billion national
PDPR developed its strong hold on this segment by focusing only on the
infant-pediatric prosthetics segment.
In its segment, PDPR hopes to repeat the success Hanger, Inc. Hanger, Inc=
currently trades on the NYSE under "HGR", has a market cap of approx. $366=
million and trades at around $18.
INFANT-PEDIATRIC PROSTHETICS MARKET
Children ages 0 to 14 comprise of 5%, or $100 million, of the total $2
billion national prosthetic market. The vast majority of this 5=
prosthetic market derives from babies born with a limb loss.
There are approximately 145,000 first time amputations each year. Of thes=
145,000 first time amputations, less than 1% or approximately 1,000 babies=
are born with a limb loss.
PDPR's the only infant-pediatric prosthetics company focusing on these
Focusing on this infant-pediatric need allows PDPR to generate a consisten=
revenue stream from childhood to adulthood. This "annuity effect" should
compound earnings year after year and enable PDPR to enjoy stable growth.
The cost from infancy to adulthood is anticipated to be over $200,000 for =
below elbow amputee. Adults will spend an additional $200,000 on their
artificial arms. Revenue growth is directly correlated with the physical
growth of the children.
PDPR MANAGEMENT TEAM
The management team of PDPR is nationally recognized as the leading
prosthetists in the infant-pediatric prosthetics field. PDRP's management=
been featured in, "Orthotics & Prosthetics Business News", written up in
"Life Magazine", and some of the fitted children have appeared on national=
TV shows, including "Good Morning America", "Maury Povich", "Phil Donahue=
The last time information was disseminated on PDPR it increased to $0.45.
PDPR developed a strong niche in the nearly $2 billion a year industry by
addressing the specialized $100 million infant-pediatric need.
PDPR is the only company specializing in the national needs of the
Infant-Pediatric Prosthetics segment.
Focusing on its niche in the infant-pediatric segment, allows PDPR to
generate a consistent revenue stream from childhood to adulthood. This
"annuity effect" should compound earnings year after year and enable PDPR =
enjoy stable growth.
Receive First Notice on Companies like PDPR (email@example.com=
The information herein is for information purposes only and should not be
construed as an offer or solicitation of an offer to buy or to sell
securities. This assembled information is based on information supplied by=
the company, press releases, SEC filings, or from other sources believed t=
be reliable, but no representation, expressed or implied, is made as to it=
accuracy, completeness or correctness. The data contained herein is subjec=
to change without notice. Small-cap companies, micro-cap companies, penny
stocks and/or thinly traded securities are inherently risky and volatile;
therefore the risk of losing some or all should be calculated. Please alwa=
do your own due diligence and consult a financial advisor. OTCFirstAlert
accepts no liability for any losses arising from an investor's reliance on=
or use of this report. Affiliates of OTCFirstAlert have been hired by a
third party and are to one million trading shares for the construction and=
dissemination of this information. OTCFirstAlert and its affiliates,
officers, directors, members and employees may hold, buy or sell common
shares of profiled companies in the open market without notice. On technic=
analysis may from time to time cause the target price to fluctuate without=
notice. Certain information included herein is forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995, including=
but not limited to, statements concerning manufacturing, marketing, growth=
and expansion. Such forward-looking information involves important risks a=
uncertainties that could affect actual results and cause them to differ
materially from expectations expressed herein.